|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Racl in human breast cancer: Ovcrexpression, mutation analysis, and characterization of a new isoform, Racl b 显示文摘 | Sehnelzer A Prechtel D Knaus U Dehne K Gerhard M Graeff H | 2000 | Oncogene2000，19，26： | 1 |
| 2 | Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | SCHMALFELDT B PRECHTEL D HARTING K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 3 | Increased expression of matrix metalloproteinases (MMP) - 2, MMP - 9, and the urokinase - type plasminogen activator is associated with progression from be- nign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Hatrting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 4 | Increased expression of matrix metalloproteinases (MMP)-2,MMP -9,and the urokinase -type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 5 | Increased expression of matrix metalloproteinases-2,-9 and the urokinse-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schrnalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 6 | Increased expression of matrix metalloproteinase( MMP-2 ), MMp-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 7 | Increased expres- sion of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Sehmalfeldt B Prechtel D Harting K | 2001 | Clirt Cancer2001，7，8： | 1 |
| 8 | Increased expression of matrix metalloproteinases (MMP)-2,MMP-9,and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 9 | Increased expression of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 10 | Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 11 | Increased expression of matrix metalloproteinases (MMP)-2,MMP-9,and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Hharting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 12 | Increased expression of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 13 | Semantic similarity analysis of user-generated content for theme-based route planning显示文摘 | Pippig K Burghardt D Prechtel N | 2013 | Journal of Location Based Services2013，7，4： | 1 |
| 14 | Increased expression of matrix metalloproteinases (MMP)-2,MMP-9,and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 15 | Increased expression of matrix metalloproteinases ( MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 16 | Increased expression of matrix metalloproteinase(MMP-2),MMP-9,and the urokinasetype plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 17 | Architecture and material properties of diatom shells provide effective mechanical protection显示文摘 | Hamm C E Merkel R Springer O Jurkoje P Maier C Prechtel K Smetacek V | 2003 | Nature2003，421，： | 1 |
| 18 | Increasedexpression of matrix metalloproteinases (MMP) 一2,MMP - 9,andthe urokinase - type plasminogen activator is associated with pro-gression from benign to advanced ovarian cancer显示文摘 | SCHMALFELDT B PRECHTEL D HARTING K | 2001 | Clin CancerRes2001，7，8： | 1 |
| 19 | Resonant accelerometer with self-test显示文摘 | Aikele M Bauer K Ficker W Neubauer F Prechtel U Schalk J Seidel H | 2001 | Sensors and Actuators A2001，，92： | 1 |
| 20 | Increased expression of matrix metalloproteinases ( MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员